16.23 0.00 (0.00%)
After hours: 5:00PM EDT
|Bid||16.23 x 1400|
|Ask||16.23 x 900|
|Day's Range||15.68 - 16.46|
|52 Week Range||8.35 - 19.11|
|Beta (3Y Monthly)||3.03|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Fate Therapeutics, Inc.'s (NASDAQ:FATE) latest earnings update in December 2018Read More...
Investors will focus on regular top and bottom-line numbers along with pipeline progress when Cronos (CRON) reports fourth-quarter results.
Fate Therapeutics (FATE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Shares of Fate Therapeutics Inc. were up 11% in premarket trade Wednesday after the company announced that the FDA had cleared its investigational new drug application for FT516, a potential therapy for patients with certain blood cancers. FT516 is a natural killer cell product engineered to make a surface protein called the CD16 Fc receptor. CD16 is a surface receptor that helps regulate an immune response where natural killer cells bind to and kill cancer cells. Cancer patients can have reduced CD16, inhibiting their bodies' tumor-killing responses. FT516's CD16 Fc receptor has been modified so that it will not have this problem -- the idea is that administering this therapy will allow for a better anti-tumor response in cancer patients. Fate Therapeutics said its initial study of FT516 will assess the safety and tolerability of three weekly doses of the therapy to treat certain later-stage blood cancers. Shares of Fate Therapeutics have gained 8% in the year to date, while the S&P 500 has gained 9.2%.
J. Wolchko became the CEO of Fate Therapeutics, Inc. (NASDAQ:FATE) in 2015. First, this article will compare CEO compensation with compensation at similar sized companies. After that, we will consider Read More...
On December 21, Vanda Pharmaceuticals (VNDA) stock closed at $24.00, which is a ~1.64% decline from its prior close of $24.40 on December 20, 2018. Vanda Pharmaceuticals stock price grew from $15.20 at the close of market on December 29, 2017, to $24.00 on December 21, 2018, reflecting ~58% YTD growth.
The 700+ hedge funds and money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the second quarter, which unveil their equity positions as of September 30. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund positions. Our extensive review […]
The American Society of Hematology meeting could "bring some excitement" this weekend in San Diego as biopharma giants take their blood cancer treatments to bat.
Every investor in Fate Therapeutics Inc (NASDAQ:FATE) should be aware of the most powerful shareholder groups. Institutions will often hold stock in bigger companies, and we expect to see insiders Read More...
Fate Therapeutics (FATE) delivered earnings and revenue surprises of -29.17% and -72.98%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The San Diego-based company said it had a loss of 31 cents per share. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a ...
If you own shares in Fate Therapeutics Inc (NASDAQ:FATE) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measureRead More...
Fate Therapeutics (FATE) delivered earnings and revenue surprises of -32.14% and -19.26%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The San Diego-based company said it had a loss of 37 cents per share. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a ...
Fate Therapeutics (NASDAQ: FATE ) releases its next round of earnings Monday. Here's Benzinga's essential guide to Fate Therapeutics' Q2 earnings report. Earnings and Revenue Analysts are expecting Fate ...
A full-blown trade war could test the resiliency of the nine-year bull market, with key groups exposed to a major correction, but a handful of sectors could thrive in the challenging conditions and find their way to new highs.
TransEnterix (TRXC) is a US-based medical device company that focuses on digitizing the interfaces between the surgeon and the patient. The stock price increased ~5.6% and closed at $3.75 on June 1. On May 31, TransEnterix announced that Louisiana State University Health New Orleans School of Medicine purchased the Senhance Surgical System, which was developed by TransEnterix.